Protein Characterization And Quantification Market Size (2024 - 2029)

Protein Characterization And Quantification Market Analysis

The Protein Characterization and Quantification Market is expected to register a CAGR of 9.5% over the forecast period.

The market was initially slightly impacted due to the COVID-19 pandemic, with elevated research on the protein involved in the SARS-CoV-2 infection process and progression of COVID-19, which increased the market growth. For instance, a study published in the Journal of Virological Methods in May 2022 highlighted using targeted mass spectrometry of a virus-based vaccine to quantify the SARS-CoV-2 spike antigen. The study demonstrated that the mass spectrometric (MS) spike protein quantification method can quantify antigens within a sample such as a vaccine or therapeutic sample. Thus, the demand for protein quantification and characterization increases in such instances, significantly impacting the studied market. However, from late 2021, the number of COVID-19 cases decreased due to the mass vaccinations and wide availability of the vaccine and diagnosis. It enabled the market to grow normally, with the resumption of research studies and diagnosis of other chronic diseases and infections. Thus, the COVID-19 outbreak positively impacted the market's growth in its preliminary phase. Moreover, the market is expected to grow at a stable pace with increasing research, characterization, and protein quantification in various chronic diseases.

Further, the protein characterization and quantification market is expected to grow further with biologics' increasing adoption, increasing R&D expenditure and government funding for proteomics, and technological advancements to contribute to market growth. For instance, according to the article published in Advanced Drug Delivery Reviews in March 2021, current therapies do not adequately address the multiple dysregulated systems following Myocardial Infarction. Hence, recent studies developed novel biologics delivery systems to address these diseases. The demand for biologics is also on the rise, driving the key developments of the market players in developing and offering more biologics. For instance, in September 2021, Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd., signed an agreement with Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd. Under the agreement, BBL offered its 15% stake to SILS, which would elevate the production of COVID-19 vaccines at SILS's facility in Pune, India.

Further, in March, Eisai Co., Ltd. received acceptance from the United States Food and Drug Administration (FDA) for Eisai's supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb) injection. The therapeutic biologic is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody to treat Alzheimer's Disease. Also, in May 2022, Prellis Biologics, Inc. signed a collaboration and license option agreement with Sanofi SA. Under the agreement, both companies would focus on generating human antibodies for targeted diseases. The research to develop drug delivery systems for biologics is expected to increase over the forecast period, positively impacting the market's growth.

Furthermore, governments and private bodies are promoting research in proteomics and protein studies by raising funds. As a result, the protein detection and quantification market is expected to grow significantly in the coming years. For instance, Novo Holdings invested over USD 40 million in a proteomics technology company, Evosep. The investment would expand the global geographical presence and proteomics portfolio. Further, in August 2021, the Minister of Innovation, Science and Industry of Canada invested over CAD 144.47 thousand (USD 107.02 thousand) to support the project 'Predict to Prevent: Advanced Proteomics Profiling for Precision Medicine' at the Université Laval, Canada. Thus, rising research and development investments are likely to boost the research activity for protein characterization and quantification, thereby boosting the market studied.

Therefore, owing to the above factors, including the rising research investments and the increasing adoption of biologics, the studied market is anticipated to grow over the analysis period. However, the high cost associated with instrumentation will likely impede market growth.

Protein Characterization And Quantification Industry Segmentation

As per the scope of the report, protein characterization involves using experimental methods that allow for the detection and isolation of a protein and its purification, as well as the characterization of its structure and function. On the other hand, protein quantification is required to determine the total protein content of a sample or a formulated product. The Protein Characterization and Quantification Market is segmented by product and services (consumables, instruments (mass spectrometry instruments, chromatography instruments, electrophoresis instruments, label-free detection instruments, spectroscopy instruments, and other instruments), and services), application (drug discovery and development, clinical diagnosis, and other applications), end-user (pharmaceutical and biotechnology companies, contract research organizations, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for the above segments.